LUNG250117P12500
- 0.00
- 0.000.00%
Pulmonx Newsroom
Wells Fargo Maintains Pulmonx(LUNG.US) With Hold Rating, Maintains Target Price $8
Citi Maintains Pulmonx(LUNG.US) With Hold Rating
Pulmonx (LUNG) Gets a Buy From Lake Street
Pulmonx Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo Maintains Pulmonx(LUNG.US) With Hold Rating, Announces Target Price $8
Express News | Pulmonx Corp. : Wells Fargo Cuts Target Price to $8 From $10
Citi Downgrades Pulmonx(LUNG.US) to Hold Rating, Cuts Target Price to $7.5
Does Pulmonx (LUNG) Have the Potential to Rally 117.74% as Wall Street Analysts Expect?
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
Pulmonx Partners With American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
Stifel Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $16
Analyst Estimates: Here's What Brokers Think Of Pulmonx Corporation (NASDAQ:LUNG) After Its Third-Quarter Report
Pulmonx | 10-Q: Q3 2024 Earnings Report
Pulmonx Analyst Ratings
Stifel Maintains Pulmonx(LUNG.US) With Buy Rating, Cuts Target Price to $16
CCORF Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $16
Piper Sandler Maintains Pulmonx(LUNG.US) With Buy Rating, Cuts Target Price to $10
Pulmonx Corporation (LUNG) Q3 2024 Earnings Call Transcript Summary
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates